An early-stage therapeutics company is developing novel T-cell-engaging bispecific antibodies that enable targeted stimulation of the immune system to kill tumor cells.

The BCBA project team will conduct a survey to evaluate and prioritize cardiovascular, metabolic, and neuro indications for an early stage company’s target discovery platform that leverages the power of comparative biology to develop therapeutics.

The project team will analyze the market opportunity for a novel NGS library preparation kit for Illumina NGS systems that, in addition to primary sequence, captures long-range information enabling large structural variant detection and haplotype phasing along with 3D chromatin architecture.

The multi-institutional project team will conduct a survey to evaluate and prioritize ocular indications for a venture-backed company’s novel gene editing platform.

Lupa Bio is a start-up company founded to advance evolutionary biology with an aim to disrupt the prescription anti-inflammatory market.  They are an innovative, Indie Bio-funded company with a founding team

The multi-institutional project team will analyze and prioritize oncology targets for drug development by an early stage, venture-backed company with an innovative medicinal chemistry platform

The multi-institutional project team will evaluate the drug discovery landscape to prioritize market entry points for a versatile human stem cell-based technology platform that can be used in preclinical testing